Encouraged by the prolonged survival observed for lupus-prone mice treated with DNase I [71], a first-in-human clinical study with single bolus i.v. administration of human DNase I was conducted as early as 1999 in patients suffering from autoimmune systemic lupus erythematosus [34]. Here, DNASE1 is linked to systemic lupus erythematosus.